Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback